A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

Manci, Natalina; Marchetti, Cláudia; Tucci, Chiara Di; Giorgini, Margherita; Espósito, F.; Palaia, Innocenza; Musella, Angela; Perniola, Giorgia; Carrone, Angela; Panici, Pierluigi Benedetti

doi:10.1016/j.ygyno.2011.04.013

Cited by 17 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoadjuvant chemotherapy before surgery has shown encouraging results in IB-IIB cervical cancer with the advent of newer chemotherapeutic agents, especially cisplatin combined with paclitaxel, topotecan, or vinorelbine. 11,15,19,20 Neoadjuvant chemotherapy using combinations of these agents has been used successfully to eradicate micrometastases and improve radical operability, and represents a significant advance in cervical cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The main objectives of NACT are significant reduction of pathological risk factors and better prevention of metastatic diseases, the potential eradication of micrometastases, and the sufficient shrinkage of the primary tumor bulk to achieve radical operability. 11,12 Several clinical trials exploring the advantages of chemotherapy before radical surgery have shown the feasibility and the efficacy of chemotherapy in cervical cancer treatment, especially in FIGO stage IB2-IIA cervical cancer. 13Y15 International Federation of Gynecology and Obstetrics stage IIB cervical cancer is characterized by a higher number of risk factors and poor prognosis relative to earlystage cervical cancer.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Guo

Liu

Wang

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Guo

Liu

Wang

et al. 2015

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“… 10 Other cisplatin-based chemotherapy regimens have also been explored in multiple clinical studies, showing a promising clinical response in a neoadjuvant setting. 11 – 16 …”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant chemotherapy in locally advanced cervical carcinoma: which is better, intravenous or intra-arterial?

Gui¹,

Shen²,

Xiang³

et al. 2014

OTT

View full text Add to dashboard Cite

PurposeThe aim of our study is to investigate the differences in therapeutic effects and clinical significance between intravenous systematic chemotherapy and intra-arterial interventional chemotherapy in stage Ib2–IIb cervical carcinomas.MethodsA retrospective analysis was performed on 93 cases of intravenous and 118 cases of intra-arterial neoadjuvant chemotherapy for stage Ib2–IIb cervical carcinomas treated in Peking Union Medical College Hospital from the year 2001 to 2010.ResultsAfter neoadjuvant chemotherapy, the overall response rate was 84.9% versus (vs) 88.2% and the operability rate was 77.4% vs 81.4%, for intravenous vs intra-arterial (P>0.05). There were no significant differences in toxicities, surgical duration, perioperative blood loss, and operative complications between these two groups. Postoperative pathological examination revealed a significantly lower parametrial infiltration in the intra-arterial group (12.5% vs 38.1%, P<0.05), while the positive vaginal margin, lymph node metastasis, and intravascular tumor embolus showed no significant differences. The intravenous group and the intra-arterial group had similar recurrence rate (16.0% vs 12.3%), distant metastasis rate (9.1% vs 8.5%), and 5 year survival rate (79.5% vs 84.9%), without significant differences.ConclusionNeoadjuvant chemotherapy with cisplatin and 5-fluorouracil are safe and effective for patients with locally advanced cervical carcinomas. The intravenous and the intra-arterial approaches present with similar chemotherapy efficacy and clinical outcome. Since it is more simple and economical, the intravenous systematic approach shows greater value in clinical application.

show abstract

“…The 2-year PFS and OS of the 38 patients treated with NACT and surgery were 79% and 95%, respectively. [36] In 2012, the Japanese Gynecologic Oncology Group reported a phase II NACT study with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage IB2 to IIB cervical squamous cell carcinoma. Sixty-six patients were treated with irinotecan (60 mg/ m 2 on days 1 and 8) and nedaplatin (80 mg/m 2 on day 1) with a 21-day interval.…”

Section: The Drug Combination and Regimen Of Nactmentioning

confidence: 99%

Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and Evolving Data

Lee¹,

Kim²,

Yoon³

et al. 2013

Neoadjuvant Chemotherapy - Increasing Relevance in Cancer Management

View full text Add to dashboard Cite

A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

Cited by 17 publications

References 29 publications

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Outcome of International Federation of Gynecology and Obstetrics Stage IIB Cervical Cancer From 2003 to 2012

Neoadjuvant chemotherapy in locally advanced cervical carcinoma: which is better, intravenous or intra-arterial?

Neoadjuvant Chemotherapy for Cervical Cancer: Rationale and Evolving Data

Contact Info

Product

Resources

About